The acquired Brugada syndrome and the paradox of choice

      Consider the following two patients. The first is female, asymptomatic, and develops marked QT prolongation while receiving intravenous procainamide for atrial fibrillation. The second is male, also asymptomatic, and develops coved-type ST-segment elevation in the right precordial leads while receiving intravenous flecainide during a diagnostic test. Most physicians would simply recommend discontinuation of procainamide and avoidance of QT-prolonging medications in the future as the only therapeutic measures needed for the first patient. In contrast, the same physicians would likely perform electrophysiologic studies and, if positive, move on to implant a defibrillator to the second patient.
      • Antzelevitch C.
      • Brugada P.
      • Borggrefe M.
      • et al.
      Brugada syndrome: report of the second consensus conference.
      How did we end up choosing such disparate recommendations for patients with drug-induced long QT syndrome (LQTS) and Brugada syndrome?
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Antzelevitch C.
        • Brugada P.
        • Borggrefe M.
        • et al.
        Brugada syndrome: report of the second consensus conference.
        Heart Rhythm. 2005; 2: 429-440
        • Jervell A.
        • Lange-Nielsen F.
        Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death.
        Am Heart J. 1957; 54: 59-68
        • Romano C.
        • Gemme G.
        • Pongiglione R.
        Aritmie cardiache rare dell'eta pediatrica.
        Clin Pediatr. 1963; 45: 656-683
        • Ward O.C.
        A new familial cardiac syndrome in children.
        J Irish Med Assoc. 1964; 54: 103-106
        • Selzer A.
        • Wray H.W.
        Quinidine syncope.
        Circulation. 1964; 30: 17-26
        • Jackman W.M.
        • Friday K.J.
        • Anderson J.L.
        • Aliot E.M.
        • Clark M.
        • Lazzara R.
        The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis.
        Prog Cardiovasc Dis. 1988; 31: 115-172
        • Sanguinetti M.C.
        • Jiang C.
        • Curran M.E.
        • Keating M.T.
        A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.
        Cell. 1995; 81: 229-307
        • Sesti F.
        • Abbott G.W.
        • Wei J.
        • et al.
        A common polymorphism associated with antibiotic-induced cardiac arrhythmia.
        Proc Natl Acad Sci U S A. 2000; 97: 10613-10618
        • Kaab S.
        • Hinterseer M.
        • Nabauer M.
        • Steinbeck G.
        Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QT-syndrome—a case-control pilot study using i.v. sotalol.
        Eur Heart J. 2003; 24: 649-657
        • Jeyaraj D.
        • Abernethy D.P.
        • Natarajan R.N.
        • et al.
        I(Kr) channel blockade to unmask occult congenital long QT syndrome.
        Heart Rhythm. 2008; 5: 2-7
        • Brugada P.
        • Brugada J.
        Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report.
        J Am Coll Cardiol. 1992; 20: 1391-1396
        • Antzelevitch C.
        The Brugada syndrome.
        J Cardiovasc Electrophysiol. 1998; 9: 513-516
        • Chen Q.
        • Kirsch G.E.
        • Zhang D.
        • et al.
        Genetic basis and molecular mechanism for idiopathic ventricular fibrillation.
        Nature. 1998; 392: 293-296
        • Brugada R.
        • Brugada J.
        • Antzelevitch C.
        • et al.
        Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts.
        Circulation. 2000; 101: 510-515
        • Wilde A.A.
        • Antzelevitch C.
        • Borggrefe M.
        • et al.
        Proposed diagnostic criteria for the Brugada syndrome: consensus report.
        Circulation. 2002; 106: 2514-2519
        • Echt D.S.
        • Liebson P.R.
        • Mitchell L.B.
        • et al.
        Mortality and morbidity in patients receiving encainide, flecainide, or placebo.
        N Engl J Med. 1991; 324: 781-788
        • Vincent G.M.
        • Schwartz P.J.
        • Denjoy I.
        • et al.
        High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment “failures.”.
        Circulation. 2009; 119: 215-221
        • Postema P.G.
        • Wolpert C.
        • Amin A.S.
        • et al.
        Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (
        Heart Rhythm. 2009; 6: 1335-1341
        • Dole V.P.
        • Nyswander M.E.
        • Kreek M.J.
        Narcotic blockade—a medical technique for stopping heroin use by addicts.
        Trans Assoc Am Physicians. 1966; 79: 122-136
        • Krantz M.J.
        • Lewkowiez L.
        • Hays H.
        • Woodroffe M.A.
        • Robertson A.D.
        • Mehler P.S.
        Torsade de pointes associated with very-high-dose methadone.
        Ann Intern Med. 2002; 137: 501-504
        • Fenichel R.R.
        • Malik M.
        • Antzelevitch C.
        • et al.
        Drug-induced torsades de pointes and implications for drug development.
        J Cardiovasc Electrophysiol. 2004; 15: 475-495
        • Haverkamp W.
        • Breithardt G.
        • Camm A.J.
        • et al.
        The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications.
        Eur Heart J. 2000; 21: 1216-1231
        • Antzelevitch C.
        Arrhythmogenic mechanisms of QT prolonging drugs: is QT prolongation really the problem?.
        J Electrocardiol. 2004; 37: 15-24
        • Towart R.
        • Linders J.T.
        • Hermans A.N.
        • et al.
        Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?.
        J Pharmacol Toxicol Methods. 2009; (In press)
        • Extramiana F.
        • Antzelevitch C.
        Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome.
        Circulation. 2004; 110: 3661-3666
        • Patel C.
        • Antzelevitch C.
        Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome.
        Heart Rhythm. 2008; 5: 585-590
        • Fish J.M.
        • Antzelevitch C.
        Role of sodium and calcium channel block in unmasking the Brugada syndrome.
        Heart Rhythm. 2004; 1: 210-217
        • Calloe K.
        • Cordeiro J.M.
        • Di Diego J.M.
        • et al.
        A transient outward potassium current activator recapitulates the electrocardiographic manifestations of Brugada syndrome.
        Cardiovasc Res. 2009; 81: 686-694
        • Malik M.
        The imprecision in heart rate correction may lead to artificial observations of drug induced QT interval changes.
        Pacing Clin Electrophysiol. 2002; 25: 209-216
        • Shimizu W.
        • Matsuo K.
        • Takagi M.
        • et al.
        Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: clinical implication of eighty-seven-lead body surface potential mapping and its application to twelve-lead electrocardiograms.
        J Cardiovasc Electrophysiol. 2000; 11: 396-404
        • Nishizaki M.
        • Sakurada H.
        • Mizusawa Y.
        • et al.
        Influence of meals on variations of ST segment elevation in patients with Brugada syndrome.
        J Cardiovasc Electrophysiol. 2008; 19: 62-68
        • Shimeno K.
        • Takagi M.
        • Maeda K.
        • Tatsumi H.
        • Doi A.
        • Yoshiyama M.
        Usefulness of multichannel Holter ECG recording in the third intercostal space for detecting type 1 Brugada ECG: comparison with repeated 12-lead ECGs.
        J Cardiovasc Electrophysiol. 2009; (In press)
        • Viskin S.
        • Justo D.
        • Halkin A.
        • Zeltser D.
        Long QT syndrome caused by noncardiac drugs.
        Prog Cardiovasc Dis. 2003; 45: 415-427
        • Zeltser D.
        • Justo D.
        • Halkin A.
        • Prokhorov V.
        • Heller K.
        • Viskin S.
        Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors.
        Medicine (Baltimore). 2003; 82: 282-290